Dr. Joanna Miriam Schaenman, MD, PhD

Dr. Schaenman practices at Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health.

Dr. Schaenman's NPI, 1790956324, was assigned on March 24, 2008. Dr. Schaenman graduated from UVA School of Medicine in 2001. Dr. Schaenman holds California license A80357.

Dr. Schaenman's primary practice is Ronald Reagan UCLA Medical Center, at 757 Westwood Plaza, Los Angeles, CA 90095 in Los Angeles County. The practice phone is (310) 825-6301.

Dr. Schaenman's primary practice is Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Schaenman to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schaenman practices, 2 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Schaenman's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Schaenman is licensed in California.

Dmand AI lists cold sores or genital herpes, immune deficiency disease, pneumonia and UTI among the conditions Dr. Schaenman treats.

CMS data shows 221 Medicare services from Dr. Schaenman across 3 procedure codes in 2024, for 112 Medicare patients. Medicare paid $22,495 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 112 Medicare patients who saw Dr. Schaenman in 2024. The largest group is 65 to 74, with 57 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 63% are also on Medicaid. Their average risk score is 5.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schaenman's median patient age at 57, with 35% women.

In 2024, Dr. Schaenman wrote 100 Medicare Part D claims for 26 patients. 89% of them were for generic drugs. CMS names the drug for 23 of them, across 2 drugs with 11 or more claims each, at $1,843 in total drug cost. In 2023, CMS named 41 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Schaenman for performance year 2024, reported as part of a group. Dr. Schaenman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Schaenman as offering telehealth.

Dmand AI links 57 papers to Dr. Schaenman, published from 2001 to 2025. 2025 was the busiest year, with 9. The most frequent topics are COVID-19, SARS-CoV-2 and Transplant Recipients. Dr. Schaenman has published most often in medRxiv. Dr. Schaenman's most frequent co-authors are Matthew Charles Altman, MD, Ofer Levy, MD, PhD and Patrice M. Becker, MD.

Dmand AI links Dr. Schaenman to 4 clinical trials, 2 of them phase 4 studies. 1 is still active or recruiting. Conditions studied include Acquired Immunodeficiency Syndrome and Slow Virus Diseases. Johns Hopkins University sponsors the most, 2.

CMS Open Payments shows 8 general payments to Dr. Schaenman from 7 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 66% of the total. Roche Molecular Systems, Inc. paid the most, $2,100.

Dr. Schaenman graduated from UVA School of Medicine in 2001.

Dr. Schaenman is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.